PTEN enhances the sensitivity of human hepatocellular carcinoma cells to sorafenib

Oncology Research

Volumn 20, Issue 2-3, 2012, Pages 113-121

  Ruan, Zhi Ping ^a   Xu, Rui ^a,b   Lv, Yi ^a   Tian, Tao ^a   Wang, Wen Juan ^a   Guo, Hui ^a   Nan, Ke Jun ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^b Shaanxi Cancer Hospital   (China)

Author keywords

Hepatocellular carcinoma; PTEN; Sorafenib

Indexed keywords

CYCLIN D1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; RAF PROTEIN; SORAFENIB; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MALE; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 84869035506     PISSN: 09650407     EISSN: 15553906     Source Type: Journal    
DOI: 10.3727/096504012X13477145152995     Document Type: Article

References (26)

1. Okuda, K. Hepatocellular carcinoma. J. Hepatol. 32:225-237; 2000.
2. Flaherty, K. T. Sorafenib: Delivering a targeted drug to the right targets. Expert Rev. Anticancer Ther. 7:617-626; 2007.
3. Keating, G. M.; Santoro, A. Sorafenib: A review of its use in advanced hepatocellular carcinoma. Drugs 69:223-240; 2009.
4. Llovet, J. M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J. F.; de Oliveira, A. C.; Santoro, A.; Raoul, J. L.; Forner, A.; Schwartz, M.; Porta, C.; Zeuzem, S.; Bolondi, L.; Greten, T. F.; Galle, P. R.; Seitz, J. F.; Borbath, I.; Haussinger, D.; Giannaris, T.; Shan, M.; Moscovici, M.; Voliotis, D.; Bruix, J. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359: 378-390; 2008.
5. Weng, L. P.; Smith, W. M.; Dahia, P. L.; Ziebold, U.; Gil, E.; Lees, J. A.; Eng, C. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death. Cancer Res. 59:5808-5814; 1999.
6. Lu, Y.; Lin, Y. Z.; LaPushin, R.; Cuevas, B.; Fang, X.; Yu, S. X.; Davies, M. A.; Khan, H.; Furui, T.; Mao, M.; Zinner, R.; Hung, M. C.; Steck, P.; Siminovitch, K.; Mills, G. B. The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene 18:7034-7045; 1999.
7. Hu, T. H.; Huang, C. C.; Lin, P. R.; Chang, H. W.; Ger, L. P.; Lin, Y. W.; Changchien, C. S.; Lee, C. M.; Tai, M. H. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer 97:1929-1940; 2003.
8. Tian, T.; Nan, K. J.; Wang, S. H.; Liang, X.; Lu, C. X.; Guo, H.; Wang, W. J.; Ruan, Z. P. PTEN regulates angiogenesis and VEGF expression through phosphatase-dependent and -independent mechanisms in HepG2 cells. Carcinogenesis 31:1211-1219; 2010.
9. Tian, T.; Nan, K. J.; Guo, H.; Wang, W. J.; Ruan, Z. P.; Wang, S. H.; Liang, X.; Lu, C. X. PTEN inhibits the migration and invasion of HepG2 cells by coordinately decreasing MMP expression via the PI3K/Akt pathway. Oncol. Rep. 23:1593-1600; 2010.
10. Kang-Park, S.; Lee, Y. I. PTEN modulates insulin-like growth factor II (IGF-II)-mediated signaling; the protein phosphatase activity of PTEN downregulates IGF-II expression in hepatoma cells. FEBS Lett. 545:203-208; 2003.
11. Meng, F.; Henson, R.; Wehbe-Janek, H.; Ghoshal, K.; Jacob, S. T.; Patel, T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocel lular cancer. Gastroenterology 133:647-658; 2007.
12. Hu, T. H.; Wang, C. C.; Huang, C. C.; Chen, C. L.; Hung, C. H.; Chen, C. H.; Wang, J. H.; Lu, S. N.; Lee, C. M.; Changchien, C. S.; Tai, M. H. Down-regulation of tumor suppressor gene PTEN, overexpression of p53, plus high proliferating cell nuclear antigen index predict poor patient outcome of hepatocellular carcinoma after resection. Oncol. Rep. 18:1417-1426; 2007.
13. Liu, L.; Cao, Y.; Chen, C.; Zhang, X.; McNabola, A.; Wilkie, D.; Wilhelm, S.; Lynch, M.; Carter, C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 66: 11851-11858; 2006.
14. Parkin, D. M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin. 55:74-108; 2005.
15. Li, J.; Yen, C.; Liaw, D.; Podsypanina, K.; Bose, S.; Wang, S. I.; Puc, J.; Miliaresis, C.; Rodgers, L.; McCombie, R.; Bigner, S. H.; Giovanella, B. C.; Ittmann, M.; Tycko, B.; Hibshoosh, H.; Wigler, M. H.; Parsons, R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947; 1997.
16. Steck, P. A.; Pershouse, M. A.; Jasser, S. A.; Yung, W. K.; Lin, H.; Ligon, A. H.; Langford, L. A.; Baumgard, M. L.; Hattier, T.; Davis, T.; Frye, C.; Hu, R.; Swedlund, B.; Teng, D. H.; Tavtigian, S. V. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15:356-362; 1997.
17. Yao, Y. J.; Ping, X. L.; Zhang, H.; Chen, F. F.; Lee, P. K.; Ahsan, H.; Chen, C. J.; Lee, P. H.; Peacocke, M.; Santella, R. M.; Tsou, H. C. PTEN/MMAC1 mutations in hepatocellular carcinomas. Oncogene 18:3181-3185; 1999.
18. Horie, Y.; Suzuki, A.; Kataoka, E.; Sasaki, T.; Hamada, K.; Sasaki, J.; Mizuno, K.; Hasegawa, G.; Kishimoto, H.; Iizuka, M.; Naito, M.; Enomoto, K.; Watanabe, S.; Mak, T. W.; Nakano, T. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J. Clin. Invest. 113:1774-1783; 2004.
19. Pruitt, K.; Der, C. J. Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett. 171:1-10; 2001.
20. Huynh, H.; Do, P. T.; Nguyen, T. H.; Chow, P.; Tan, P. H.; Quach, T. H.; Van, T.; Soo, K. C.; Tran, E. Extra-cellular signal-regulated kinase induces cyclin D1 and Cdk-2 expression and phosphorylation of retinoblastoma in hepatocellular carcinoma. Int. J. Oncol. 25:1839-1847; 2004.
21. Martin, A. P.; Park, M. A.; Mitchell, C.; Walker, T.; Rahmani, M.; Thorburn, A.; Haussinger, D.; Reinehr, R.; Grant, S.; Dent, P. BCL-2 family inhibitors enhance his tone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing. Mol. Pharmacol. 76:327-341; 2009.
22. Jane, E. P.; Premkumar, D. R.; Pollack, I. F. Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. J. Pharmacol. Exp. Ther. 319:1070-1080; 2006.
23. Yu, C.; Friday, B. B.; Lai, J. P.; Yang, L.; Sarkaria, J.; Kay, N. E.; Carter, C. A.; Roberts, L. R.; Kaufmann, S. H.; Adjei, A. A. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: Induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol. Cancer Ther. 5:2378-2387; 2006.
24. Raftopoulou, M.; Etienne-Manneville, S.; Self, A.; Nicholls, S.; Hall, A. Regulation of cell migration by the C2 domain of the tumor suppressor PTEN. Science 303: 1179-1181; 2004.
25. Freeman, D. J.; Li, A. G.; Wei, G.; Li, H. H.; Kertesz, N.; Lesche, R.; Whale, A. D.; Martinez-Diaz, H.; Rozengurt, N.; Cardiff, R. D.; Liu, X.; Wu, H. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell 3:117-130; 2003.
26. Chalhoub, N.; Baker, S. J. PTEN and the PI3-kinase pathway in cancer. Annu. Rev. Pathol. 4:127-150; 2009.